{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T17:23:06Z","timestamp":1648920186251},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T00:00:00Z","timestamp":1400630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00277-014-2105-1","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T11:05:39Z","timestamp":1400583939000},"page":"1725-1733","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed\/refractory chronic lymphocytic leukaemia (CLL)\u2014a single region experience on consecutive patients"],"prefix":"10.1007","volume":"93","author":[{"given":"S.","family":"Eketorp Sylvan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ipek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,21]]},"reference":[{"issue":"9583","key":"2105_CR1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","volume":"370","author":"D Catovsky","year":"2007","unstructured":"Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370(9583):230\u2013239","journal-title":"Lancet"},{"issue":"3","key":"2105_CR2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","volume":"107","author":"BF Eichhorst","year":"2006","unstructured":"Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107(3):885\u2013891","journal-title":"Blood"},{"issue":"9747","key":"2105_CR3","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164\u20131174","journal-title":"Lancet"},{"issue":"18","key":"2105_CR4","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","volume":"23","author":"MJ Keating","year":"2005","unstructured":"Keating MJ, O\u2019Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 23(18):4079\u20134088","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"18","key":"2105_CR5","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","volume":"23","author":"W Wierda","year":"2005","unstructured":"Wierda W, O\u2019Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D et al (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 23(18):4070\u20134078","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2105_CR6","doi-asserted-by":"crossref","unstructured":"Eketorp Sylvan S, Hansson L, Karlsson C, Norin S, Lundin J, \u00d6sterborg A (2013) Outcomes of patients with fludarabine-refractory chronic lymphocytic leukaemia (CLL)\u2014a population-based study from a well-defined geographic region. Leuk Lymphoma (in press)","DOI":"10.3109\/10428194.2013.827786"},{"issue":"10","key":"2105_CR7","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1080\/10428190701573257","volume":"48","author":"CS Tam","year":"2007","unstructured":"Tam CS, O\u2019Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S et al (2007) The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 48(10):1931\u20131939","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2105_CR8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","volume":"82","author":"MH Gilleece","year":"1993","unstructured":"Gilleece MH, Dexter TM (1993) Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82(3):807\u2013812","journal-title":"Blood"},{"issue":"6","key":"2105_CR9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2141.2008.07557.x","volume":"144","author":"JG Gribben","year":"2009","unstructured":"Gribben JG, Hallek M (2009) Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 144(6):818\u2013831. doi: 10.1111\/j.1365-2141.2008.07557.x","journal-title":"Br J Haematol"},{"issue":"1","key":"2105_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2010.09.001","volume":"25","author":"M Hallek","year":"2011","unstructured":"Hallek M, Pflug N (2011) State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 25(1):1\u20139. doi: 10.1016\/j.blre.2010.09.001","journal-title":"Blood Rev"},{"issue":"10","key":"2105_CR11","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99(10):3554\u20133561","journal-title":"Blood"},{"issue":"3","key":"2105_CR12","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V et al (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100(3):768\u2013773. doi: 10.1182\/blood-2002-01-0159","journal-title":"Blood"},{"issue":"4","key":"2105_CR13","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A Osterborg","year":"1997","unstructured":"Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol Off J Am Soc Clin Oncol 15(4):1567\u20131574","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"35","key":"2105_CR14","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","volume":"25","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 25(35):5616\u20135623. doi: 10.1200\/JCO.2007.12.9098","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"2105_CR15","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","volume":"85","author":"H Dohner","year":"1995","unstructured":"Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85(6):1580\u20131589","journal-title":"Blood"},{"issue":"11","key":"2105_CR16","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1038\/leu.2009.146","volume":"23","author":"A Osterborg","year":"2009","unstructured":"Osterborg A, Foa R, Bezares RF, Dearden C, Dyer MJ, Geisler C et al (2009) Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23(11):1980\u20131988. doi: 10.1038\/leu.2009.146","journal-title":"Leukemia"},{"issue":"24","key":"2105_CR17","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","volume":"27","author":"S Stilgenbauer","year":"2009","unstructured":"Stilgenbauer S, Zenz T, Winkler D, Buhler A, Schlenk RF, Groner S et al (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol Off J Am Soc Clin Oncol 27(24):3994\u20134001. doi: 10.1200\/JCO.2008.21.1128","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"2105_CR18","first-page":"1435","volume":"90","author":"NC Osuji","year":"2005","unstructured":"Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D (2005) The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 90(10):1435\u20131436","journal-title":"Haematologica"},{"issue":"10","key":"2105_CR19","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1002\/cncr.22263","volume":"107","author":"M Fiegl","year":"2006","unstructured":"Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F et al (2006) Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 107(10):2408\u20132416. doi: 10.1002\/cncr.22263","journal-title":"Cancer"},{"issue":"18","key":"2105_CR20","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","volume":"20","author":"KR Rai","year":"2002","unstructured":"Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA et al (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol Off J Am Soc Clin Oncol 20(18):3891\u20133897","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2 Suppl 5","key":"2105_CR21","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1053\/j.seminoncol.2006.01.027","volume":"33","author":"A Osterborg","year":"2006","unstructured":"Osterborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H (2006) Strategies in the management of alemtuzumab-related side effects. Semin Oncol 33(2 Suppl 5):S29\u2013S35. doi: 10.1053\/j.seminoncol.2006.01.027","journal-title":"Semin Oncol"},{"issue":"1","key":"2105_CR22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2141.2008.07451.x","volume":"144","author":"C Karlsson","year":"2009","unstructured":"Karlsson C, Lundin J, Kimby E, Kennedy B, Moreton P, Hillmen P et al (2009) Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 144(1):78\u201385. doi: 10.1111\/j.1365-2141.2008.07451.x","journal-title":"Br J Haematol"},{"issue":"2","key":"2105_CR23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00277-013-1966-z","volume":"93","author":"M Fiegl","year":"2014","unstructured":"Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y et al (2014) Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Ann Hematol 93(2):267\u2013277. doi: 10.1007\/s00277-013-1966-z","journal-title":"Ann Hematol"},{"key":"2105_CR24","volume-title":"World Health Organization classification of tumours","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumours. IARC Press, Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon"},{"issue":"12","key":"2105_CR25","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446\u20135456","journal-title":"Blood"},{"issue":"12","key":"2105_CR26","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O\u2019Brien S et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87(12):4990\u20134997","journal-title":"Blood"},{"issue":"24","key":"2105_CR27","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","volume":"26","author":"JR Anderson","year":"2008","unstructured":"Anderson JR, Cain KC, Gelber RD (2008) Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol Off J Am Soc Clin Oncol 26(24):3913\u20133915. doi: 10.1200\/JCO.2008.16.1000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"2105_CR28","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","volume":"103","author":"G Lozanski","year":"2004","unstructured":"Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103(9):3278\u20133281. doi: 10.1182\/blood-2003-10-3729","journal-title":"Blood"},{"issue":"4","key":"2105_CR29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2011.08965.x","volume":"156","author":"A Cortelezzi","year":"2012","unstructured":"Cortelezzi A, Gritti G, Laurenti L, Cuneo A, Ciolli S, Di Renzo N et al (2012) An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed\/refractory chronic lymphocytic leukaemia patients. Br J Haematol 156(4):481\u2013489. doi: 10.1111\/j.1365-2141.2011.08965.x","journal-title":"Br J Haematol"},{"issue":"11","key":"2105_CR30","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/leu.2009.148","volume":"23","author":"A Cortelezzi","year":"2009","unstructured":"Cortelezzi A, Pasquini MC, Gardellini A, Gianelli U, Bossi A, Reda G et al (2009) Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 23(11):2027\u20132033. doi: 10.1038\/leu.2009.148","journal-title":"Leukemia"},{"issue":"7","key":"2105_CR31","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/cncr.26474","volume":"118","author":"TD Shanafelt","year":"2012","unstructured":"Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF et al (2012) Hematologist\/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL). Cancer 118(7):1827\u20131837. doi: 10.1002\/cncr.26474","journal-title":"Cancer"},{"key":"2105_CR32","doi-asserted-by":"crossref","unstructured":"Moreno C, Montillo M, Panayiotis P, Bloor A, Dupuis J, Schuh A, et al. (2013) A Multicenter, phase iv observational study of ofatumumab in chronic lymphocytic leukemia (CLL): a European Research Initiative on CLL (ERIC) Study. Abstract American Society of Hematology Annual Meeting and Exposition, New Orleans, LA","DOI":"10.1182\/blood.V122.21.1645.1645"},{"issue":"Suppl 5","key":"2105_CR33","doi-asserted-by":"crossref","first-page":"v162","DOI":"10.1093\/annonc\/mdq180","volume":"21","author":"B Eichhorst","year":"2010","unstructured":"Eichhorst B, Hallek M, Dreyling M, Group EGW (2010) Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO 21(Suppl 5):v162\u2013v164. doi: 10.1093\/annonc\/mdq180","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"issue":"9","key":"2105_CR34","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00277-011-1192-5","volume":"90","author":"M Fiegl","year":"2011","unstructured":"Fiegl M, Falkner F, Steurer M, Zojer N, Hopfinger G, Haslbauer F et al (2011) Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Ann Hematol 90(9):1083\u20131091. doi: 10.1007\/s00277-011-1192-5","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2105-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2105-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2105-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T17:14:56Z","timestamp":1597857296000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2105-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,21]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["2105"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2105-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,21]]}}}